{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T08:58:32Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d5-ce83-7e02-8c7a-1a0094f84f42\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: cyclothiazide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 r", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d5-ce74-77f2-95ff-bc27e1435837\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: cyclothiazide\nRegistry id: vr.tr.cyclothiazide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:55:04+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5199066", "registryId": "vr.tr.cyclothiazide", "name": "cyclothiazide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5199066/", "model": { "registry_id": "vr.tr.cyclothiazide", "name": "cyclothiazide", "purpose": "Enable an AI agent to identify cyclothiazide, assess the suitability of a particular sample, and determine which handling or research actions its evidence supports.", "definition": "Cyclothiazide is a synthetic benzothiadiazine sulfonamide with thiazide diuretic activity that is also used experimentally as a positive allosteric modulator of AMPA-type glutamate receptors, chiefly by reducing receptor desensitization.", "scope_statement": "This model owns cyclothiazide as the chemical substance registered as vr.tr.cyclothiazide in PHY / PHY.MAT, including molecular identity, sample composition, physical state, experimentally supported activity, and use constraints.", "in_scope": [ "Molecular identity and identifier reconciliation", "Stereochemical composition, purity, and impurities of samples", "Solid-state properties, dissolution, and solution stability", "Cyclothiazide activity in explicitly identified experimental systems", "Evidence governing handling, storage, disposal, and permitted use" ], "out_of_scope": [ "Finished medicines and their excipients, packaging, or brand identities", "Patient diagnosis, prescribing, and treatment decisions", "AMPA receptors and renal transporters as independently modelled biological entities", "Manufacturing processes and laboratory protocols as executable workflows", "Other thiazide substances and other AMPA receptor modulators" ], "distinguishing_features": [ "Match the molecular structure as well as CAS 2259-96-3 and PubChem CID 2910; a similar name or shared drug class is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclothiazide)", "Check for molecular formula C14H16ClN3O4S2 and a molecular mass of approximately 389.9 g/mol, while recognising that formula and mass alone cannot resolve isomers. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclothiazide)", "Confirm the norbornenyl-substituted benzothiadiazine dioxide structure rather than identifying the sample merely as a thiazide. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclothiazide)", "Distinguish AMPA receptor modulation from direct agonism: cyclothiazide is described as a positive allosteric modulator that inhibits desensitization, but that activity is not an identity assay. [Tocris](https://www.tocris.com/pharmacology/ampa-receptors/modulators)" ], "characteristics": [ { "name": "Chemical identity", "kind": "relation", "unit_or_values": "vr.tr.cyclothiazide; CAS 2259-96-3; PubChem CID 2910; structure representation", "why_it_matters": "Connects the registry entry to external records while requiring structural agreement." }, { "name": "Stereochemical specification", "kind": "category", "unit_or_values": "Explicitly assigned stereochemistry; characterised mixture; unspecified", "why_it_matters": "Prevents an unspecified identity record from being interpreted as a certified individual stereoisomer." }, { "name": "Assayed cyclothiazide content", "kind": "measurement", "unit_or_values": "% w/w or mol/mol, with analytical method and reporting basis", "why_it_matters": "Supports preparation calculations and distinguishes actual content from chromatographic area purity." }, { "name": "Impurity and residual-solvent profile", "kind": "measurement", "unit_or_values": "Named components in % w/w, ppm, or explicitly identified analytical response units", "why_it_matters": "Determines whether a lot can support the intended analytical or biological use." }, { "name": "Physical and solid-state form", "kind": "state", "unit_or_values": "Observed phase; characterised crystal or amorphous form; water or solvent content; unknown", "why_it_matters": "Makes dissolution and storage observations attributable to the material actually tested." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting or decomposition range in °C, with method; boiling data only when experimentally supported", "why_it_matters": "Avoids treating decomposition as boiling or transferring an unsupported constant between material forms." }, { "name": "Conditional solubility", "kind": "measurement", "unit_or_values": "mg/mL or mmol/L with solvent, temperature, pH where applicable, and equilibration method", "why_it_matters": "Determines whether an intended preparation can contain dissolved cyclothiazide at the stated concentration." }, { "name": "Solution integrity", "kind": "state", "unit_or_values": "Verified dissolved and intact; precipitated; chemically degraded; unverified", "why_it_matters": "Separates nominal preparation concentration from the condition of the material during use." }, { "name": "AMPA modulation response", "kind": "measurement", "unit_or_values": "Concentration in µmol/L; current ratio, desensitization time constant in ms, or defined assay response", "why_it_matters": "Records a measured effect together with receptor composition and experimental conditions." }, { "name": "Use and hazard evidence", "kind": "relation", "unit_or_values": "Dated supplier SDS, lot certificate, jurisdictional identity record, and applicable use restriction", "why_it_matters": "Grounds handling and eligibility decisions in applicable documents rather than inferred drug-class properties." } ], "affordances": [ "Reconcile a candidate identity record against cyclothiazide identifiers and molecular structure.", "Assess whether a cyclothiazide lot has sufficient identity, composition, and quality evidence for a stated use.", "Calculate a proposed solution concentration from assayed content and verify its feasibility against conditional solubility evidence.", "Compare cyclothiazide activity measurements only across sufficiently documented experimental conditions.", "Flag precipitation, degradation, or uncharacterised impurities that undermine interpretation of a preparation.", "Determine supported storage, handling, and disposal actions from applicable safety and stability records." ], "agent_conduct": { "may": [ "Describe cyclothiazide's diuretic use and its separate role as a research tool for glutamate receptors.", "Keep clinical facts and laboratory findings clearly apart." ], "must_not": [ "Recommend, dose or supply it to a person without a prescriber's decision.", "Present research effects on brain receptors as therapeutic uses.", "Ignore electrolyte disturbances in people taking diuretics." ], "requires_human": [ "Any decision to start, stop or change treatment." ] }, "ethics": { "considerations": [ "Mixing research and clinical claims can mislead patients about what a drug does." ], "affected_parties": [ "Patients", "Research staff", "Prescribers" ] }, "owners": { "steward": "The marketing authorisation holder where it is licensed; the prescriber answers for each use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity cannot be settled by sight; tablets or research powders must be confirmed by label and records." ], "failure_modes_and_hazards": [ "Low potassium or sodium and dehydration, as with other thiazides.", "In research use, its effects on brain receptors can promote seizures in animals." ], "what_it_is_for": [ "Cyclothiazide is encountered in pharmacological research on AMPA receptor responses and receptor desensitization.", "Its thiazide diuretic activity provides a separate context for interpreting historical medicinal use and experimental effects." ], "standards_and_regulation": [ "The United Nations Economic Commission for Europe's Globally Harmonized System of Classification and Labelling of Chemicals provides a framework for communicating applicable chemical hazards through national implementations." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5199066: cyclothiazide", "url": "https://www.wikidata.org/wiki/Q5199066", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Cyclothiazide", "url": "https://en.wikipedia.org/wiki/Cyclothiazide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "molecular-identity", "name": "Molecular identity", "description": "Establish what the cyclothiazide registry entry denotes and how candidate records map to it.", "rationale": "A thiazide name, pharmacological label, or formula cannot alone establish cyclothiazide identity.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Reconcile external identifiers with a chemically explicit representation.", "findings": [ { "id": "identity-anchor", "name": "Identity anchor", "description": "PubChem associates cyclothiazide with CID 2910 and CAS 2259-96-3; candidate records should also agree structurally. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclothiazide)", "questions": [ { "text": "Does the candidate record's molecular structure agree with the cyclothiazide reference structure?", "kind": "definition", "id": "identity-anchor-q01" }, { "text": "Which authoritative record supports each identifier, and when was it checked?", "kind": "provenance", "id": "identity-anchor-q02" } ] } ] }, { "id": "stereochemistry-and-boundaries", "name": "Stereochemistry and boundaries", "description": "Distinguish molecular identity from sample stereochemistry and commercial presentation.", "findings": [ { "id": "represented-chemical-entity", "name": "Represented chemical entity", "description": "An unspecified structure record does not establish the stereochemical composition, solvation state, or formulation of a physical sample.", "questions": [ { "text": "Which stereochemical assignments or mixture proportions are explicitly supported for this cyclothiazide sample?", "kind": "measurement", "id": "represented-chemical-entity-q01" }, { "text": "Does the supplied name denote cyclothiazide itself, a particular material form, or a product containing it?", "kind": "boundary", "id": "represented-chemical-entity-q02" } ] } ] } ] }, { "id": "lot-composition-and-quality", "name": "Lot composition and quality", "description": "Record evidence that a particular lot contains cyclothiazide at a usable and known quality.", "rationale": "Unverified content or composition can invalidate concentration calculations and biological comparisons.", "layers": [ { "id": "analytical-confirmation", "name": "Analytical confirmation", "description": "Connect identity and content claims to measurements on the actual lot.", "findings": [ { "id": "identity-and-content-evidence", "name": "Identity and content evidence", "description": "Identity testing, quantitative assay, and chromatographic purity answer different questions and should remain distinguishable.", "questions": [ { "text": "Which lot-specific measurements establish that the principal component is cyclothiazide?", "kind": "provenance", "id": "identity-and-content-evidence-q01" }, { "text": "Is the reported purity a mass-based assay, chromatographic area percentage, or another quantity?", "kind": "measurement", "id": "identity-and-content-evidence-q02" } ] } ] }, { "id": "minor-components", "name": "Minor components", "description": "Account for components that alter weighed content or experimental interpretation.", "findings": [ { "id": "composition-dependent-suitability", "name": "Composition-dependent suitability", "description": "Water, residual solvents, unidentified peaks, and any resolved stereochemical components need evidence before a lot is accepted for its intended use.", "questions": [ { "text": "What impurity, water, and residual-solvent measurements are available for this cyclothiazide lot?", "kind": "measurement", "id": "composition-dependent-suitability-q01" }, { "text": "Do the documented composition and analytical limits meet the requirements of the intended assay or reference-material use?", "kind": "action", "id": "composition-dependent-suitability-q02" } ] } ] } ] }, { "id": "physical-form-and-preparations", "name": "Physical form and preparations", "description": "Describe the material state and the conditions under which cyclothiazide preparations remain usable.", "rationale": "A weighed amount does not establish the dissolved, intact concentration delivered to an experiment.", "layers": [ { "id": "solid-and-thermal-state", "name": "Solid and thermal state", "description": "Record observed form and experimentally supported thermal behaviour.", "findings": [ { "id": "form-specific-properties", "name": "Form-specific properties", "description": "Treat solid-form assignments and thermal values as evidence-dependent properties of characterised material.", "questions": [ { "text": "What evidence characterises the solid form and any associated water or solvent in this cyclothiazide sample?", "kind": "measurement", "id": "form-specific-properties-q01" }, { "text": "Does a reported thermal event represent melting, solvent loss, or decomposition, and under what conditions?", "kind": "measurement", "id": "form-specific-properties-q02" } ] } ] }, { "id": "dissolution-and-stability", "name": "Dissolution and stability", "description": "Connect preparation conditions to dissolved concentration and integrity over time.", "findings": [ { "id": "usable-solution", "name": "Usable solution", "description": "Solvent compatibility, dilution behaviour, and storage stability require separate evidence for stock and working solutions.", "questions": [ { "text": "What dissolved concentration is supported in the specified solvent or assay medium at the stated temperature and pH?", "kind": "measurement", "id": "usable-solution-q01" }, { "text": "What measurements establish that cyclothiazide remains dissolved and chemically intact after dilution and storage?", "kind": "measurement", "id": "usable-solution-q02" }, { "text": "When should a preparation be rechecked or rejected because its concentration or integrity is uncertain?", "kind": "action", "id": "usable-solution-q03" } ] } ] } ] }, { "id": "biological-activity-and-interpretation", "name": "Biological activity and interpretation", "description": "Record cyclothiazide effects without treating its pharmacological labels as universal assay outcomes.", "rationale": "Its diuretic classification and experimental AMPA modulation concern different systems and do not establish target selectivity.", "layers": [ { "id": "ampa-response", "name": "AMPA response", "description": "Specify the experimental conditions supporting an AMPA modulation claim.", "findings": [ { "id": "desensitization-modulation", "name": "Desensitization modulation", "description": "Primary research has investigated cyclothiazide potentiation in AMPA-driven rat hippocampal release experiments; such results retain their experimental context. [Research article](https://pmc.ncbi.nlm.nih.gov/articles/PMC1565195/)", "questions": [ { "text": "Which receptor composition, biological preparation, agonist exposure, and cyclothiazide concentration produced the reported effect?", "kind": "provenance", "id": "desensitization-modulation-q01" }, { "text": "Does the endpoint measure desensitization directly or an indirect response such as transmitter release?", "kind": "measurement", "id": "desensitization-modulation-q02" }, { "text": "What controls distinguish cyclothiazide modulation from vehicle effects and changes in preparation viability?", "kind": "action", "id": "desensitization-modulation-q03" } ] } ] }, { "id": "other-effects-and-transfer", "name": "Other effects and transfer", "description": "Bound conclusions about renal activity, other targets, and transfer between experimental systems.", "findings": [ { "id": "activity-is-not-selectivity", "name": "Activity is not selectivity", "description": "Cyclothiazide is classified as a thiazide diuretic, but that classification does not establish every target effect or its relevance at a particular experimental concentration. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclothiazide)", "questions": [ { "text": "Which primary experiments establish renal transport effects or additional receptor effects for cyclothiazide itself?", "kind": "provenance", "id": "activity-is-not-selectivity-q01" }, { "text": "At the intended concentration and exposure duration, which competing biological effects remain unresolved?", "kind": "boundary", "id": "activity-is-not-selectivity-q02" } ] } ] } ] }, { "id": "handling-and-use-constraints", "name": "Handling and use constraints", "description": "Connect decisions about cyclothiazide material to applicable safety, storage, and regulatory evidence.", "rationale": "A pharmacological history or supplier listing does not establish current clinical eligibility or safe laboratory handling conditions.", "layers": [ { "id": "hazard-and-exposure-evidence", "name": "Hazard and exposure evidence", "description": "Identify the safety information applicable to the supplied material and proposed operation.", "findings": [ { "id": "documented-handling-basis", "name": "Documented handling basis", "description": "Hazard classifications and exposure limits must be traced to applicable records; absent values remain unknown.", "questions": [ { "text": "Which current SDS applies to this cyclothiazide material, and what classification and handling measures does it specify?", "kind": "provenance", "id": "documented-handling-basis-q01" }, { "text": "Is a substance-specific occupational exposure limit established in the relevant jurisdiction, or is none documented?", "kind": "provenance", "id": "documented-handling-basis-q02" }, { "text": "Which containment, storage, and disposal actions are supported for the proposed powder or solution operation?", "kind": "action", "id": "documented-handling-basis-q03" } ] } ] }, { "id": "regulatory-and-grade-boundaries", "name": "Regulatory and grade boundaries", "description": "Separate chemical registration, supplier grade, and authorisation of medicinal products.", "findings": [ { "id": "permitted-use-basis", "name": "Permitted-use basis", "description": "Use eligibility depends on the material's documented grade and applicable jurisdictional records, with medicinal-product decisions linked to neighbouring models.", "questions": [ { "text": "Which EC or other jurisdictional chemical identity records, if any, verifiably correspond to cyclothiazide?", "kind": "provenance", "id": "permitted-use-basis-q01" }, { "text": "What documented restrictions govern this lot's intended research, analytical, or manufacturing use?", "kind": "action", "id": "permitted-use-basis-q02" }, { "text": "Which claims concern an authorised finished medicine rather than the cyclothiazide substance itself?", "kind": "boundary", "id": "permitted-use-basis-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This account is based on recall, without source consultation.", "Verify current pharmaceutical availability, jurisdiction-specific regulatory status and any applicable pharmacopoeial monograph.", "Verify stereochemical composition, purity, solubility, thermal properties and supplier-specific hazard classification before describing a particular material." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "2259-96-3", "note": "Identifier for cyclothiazide; stereochemical composition and material grade require separate specification." }, { "scheme": "Molecular formula", "value_or_pattern": "C14H16ClN3O4S2", "note": "Describes elemental composition, not stereochemistry or purity." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical pharmaceutical use as a thiazide diuretic for hypertension and oedema.", "Laboratory investigation of AMPA receptor desensitization and glutamatergic synaptic transmission." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "Approximately 389.88", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Diuretic activity can cause fluid depletion, hypotension and electrolyte disturbances, including hypokalaemia.", "Thiazide pharmacology includes risks of hyperuricaemia and impaired glucose tolerance.", "Enhancement of excitatory neurotransmission can produce epileptiform activity in experimental preparations.", "Limited aqueous solubility can complicate experimental dosing and interpretation of nominal concentrations." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Chlorothiazide", "difference": "A distinct thiazide diuretic with a different molecular structure; it is not another name for cyclothiazide." }, { "name": "Hydrochlorothiazide", "difference": "A distinct thiazide diuretic; shared drug-class membership does not establish equivalent AMPA receptor effects." }, { "name": "AMPA", "difference": "AMPA directly activates AMPA receptors, whereas cyclothiazide modulates their response to agonists." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of cyclothiazide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "What stereochemical composition is represented by commonly supplied cyclothiazide materials, and which differences have demonstrated effects on activity?", "Which solid forms, melting or decomposition ranges, and solvent-dependent solubilities are supported by reproducible measurements on characterised material?", "How long do cyclothiazide stock and working solutions remain dissolved and chemically intact under specified storage and assay conditions?", "Which concentration-dependent effects on non-AMPA targets could confound its use as an AMPA desensitization inhibitor?", "Which current EC identity, jurisdiction-specific hazard classifications, exposure limits, and use restrictions are verified for the exact material concerned?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 30 } }